Why did XAIR's Q3 2025 earnings outperform forecasts?

Beyond Air's Q3 2025 earnings outperformed forecasts due to several key factors: 1. **Revenue Growth**: The company reported a significant increase in revenue, with $1.1 million for the fiscal third quarter of 2025, compared to $0.4 million in the same period the previous year. This 175% year-over-year growth was driven by new hospital signings and contract renewals for their LungFit PH system. 2. **Gross Profit Improvement**: Despite a $0.2 million loss in gross profit, the company improved significantly from a $0.4 million loss in the same period the previous year. This improvement reflects enhanced operational efficiency and cost management. 3. **Strategic Advances**: Beyond Air has made notable progress in its Beyond Cancer initiative, with a Phase Ib trial for nitric oxide therapy in late-stage cancer patients underway. These strategic developments are likely to contribute to future revenue growth and market expansion. 4. **International Expansion**: The company expanded its global reach with new distribution agreements in France, Turkey, Romania, and Morocco, bringing its total international presence to 18 countries. This expansion is expected to open up new markets and generate additional revenue streams. In summary, Beyond Air's Q3 2025 earnings outperformed forecasts due to robust revenue growth, improved gross profit, strategic advances in their Beyond Cancer initiative, and international expansion. These factors collectively contributed to the company's financial performance and future growth potential.